Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

2,999 public trials 572 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Recruiting

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

NCT04840602

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +18 more
Locations
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
  • UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
View all 136 locations
View Trial Details
Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Local Institution - 0366 Los Alamitos, California, United States
  • Local Institution - 0272 San Diego, California, United States
  • Local Institution - 0273 West Hollywood, California, United States
  • Local Institution - 0381 Aurora, Colorado, United States
View all 266 locations
View Trial Details
Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Research Site Duarte, California, United States
  • Research Site Irvine, California, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site Boston, Massachusetts, United States
View all 43 locations
View Trial Details
Recruiting

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Arizona /ID# 251405 Phoenix, Arizona, United States
  • Highlands Oncology Group - Springdale /ID# 267742 Springdale, Arkansas, United States
  • Rocky Mountain Cancer Centers - Aurora /ID# 268574 Aurora, Colorado, United States
  • Medical Oncology Hematology Consultants /ID# 268560 Newark, Delaware, United States
View all 46 locations
View Trial Details
Recruiting

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

NCT07073547

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Research Site Phoenix, Arizona, United States
  • Research Site Duarte, California, United States
  • Research Site Denver, Colorado, United States
  • Research Site Tampa, Florida, United States
View all 13 locations
View Trial Details
Recruiting

Teclistamab-Daratumumab in AL Amyloidosis

NCT07110844

Conditions
Amyloid Light-chain Amyloidosis, Amyloidosis, Immune System Diseases, +10 more
Locations
  • Boston Medical Center Boston, Massachusetts, United States
  • Columbia University Irving Medical Center New York, United States
  • Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details

Related conditions